Corcept's Phase III trial of ovarian cancer therapy shows PFS improvement

Corcept Therapeutics' Phase III ROSELLA trial combining oral relacorilant with nab-paclitaxel for platinum-resistant ovarian cancer met its primary endpoint of improved progression-free survival.